

July 26, 2012
Tokyo, Japan
Micron, Inc.

PRESS RELEASE

Collaboration agreement between Micron, Inc. and Protech Pharmaservices Corporation for the joint development of imaging clinical trial network in Asia.

Micron, Inc. (Henceforth “Micron”, Headquarters: Tokyo, Japan) and Protech Pharmaservices Corporation (Henceforth “PPC”, Headquarters: Taipei) have entered into a collaboration agreement regarding international collaborative imaging trials in Asia.

Recent years in drug development have seen the wide use and increasing importance of imaging technology to accurately evaluate drug efficacy and safety in shorter period of time, compared to conventional clinical trials. In particular, this trend is clearly evident in malignant tumor and central nervous system disease studies. A great number of clinical trials use imaging technology as primary endpoints to conduct appropriate data collection and analysis. Meanwhile, globalization has sped up new drug development, thus many international collaborative clinical trials are being conducted in Asia.

Currently, there are demands for the collection and analysis of high quality international-level clinical imaging data. Therefore, imaging technology is becoming more popular. For that reason, we have created an imaging clinical trial network in Asia to meet the needs of companies from around the world. Since PPC offers clinical trial support for drug development throughout Asia Pacific, Micron and PPC have entered into agreement for the purpose of constructing a network for international imaging clinical trial collaboration.

As an imaging CRO, Micron is supporting the efficient drug development with PET, MRI, CT and other imaging applications in the fields of Oncology and CNS. PPC will provide its clinical network in Taiwan, Korea, and China.

PPC is a leading CRO with Headquarters in Taiwan, commissioned international clinical trials, especially in Taiwan, Korea, and China, and offers high quality services

in non-clinical and clinical trials. In addition to traditional CRO services, PPC offers central laboratory and bioanalytical laboratory services with high standards of quality, authenticated by College of American Pathologists (CAP) and Good Laboratory Practices (GLP), respectively.

In the future, Micron will promote standardization and systematization in imaging technology under the partnership with PPC, which will further strengthen our system of imaging clinical trials.

Outline of each company

Micron Inc.

Established: October, 2005

Headquarters: Tokyo, Japan

President and CEO: Makoto Sato

Main Services: Imaging related technical support and clinical trial support

Protech Pharmaservices Corporation

Established: April, 1997

Headquarters: Taipei, Taiwan

President and CEO: Jason Chen

Main Services: Clinical trial support (Taiwan, Korea, China, Japan, Singapore, Malaysia), Central laboratory and Bioanalytical laboratory Services

Contact information for inquiries

Micron, Inc.

Contacts: Michita Sato, Business Development Division (for companies in Japan)

Michael Tintiuc, Director of Foreign Affairs (for companies outside of Japan)

TEL: +81-3-6268-0305

E-mail: info@micron-kobe.com

Company Website: <http://www.micron-kobe.com>